At a glance
ClinicalIndex Comparison RecordN/ACompleted· 15 enrolled
Drug / intervention
CLS-AXdrug
Likely dose
CLS-AX injectable suspension (dose from Parent study CLS1002-101)AI-extracted
Key inclusion· 1
- ✓Completed Parent study CLS1002-101 in Cohort 2, Cohort 3, or Cohort 4
Key exclusion· 3
- ✕Enrolled in Parent study as Cohort 1
- ✕Received prohibited medication in Parent study
- ✕Pregnant or lactating women of childbearing potential
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Extension Study to Evaluate the Long-term Outcomes of Subjects Following CLS-AX Administration for Age-related Macular Degeneration in the CLS-AX CLS1002-101 Study
In Brief
An observational study evaluating CLS-AX for Neovascular Age-related Macular Degeneration. Completed, enrolled 15 participants across 7 sites.
Detailed Summary
This is an open-label, non-interventional extension study of up to 12 weeks in duration in subjects completing Cohorts 2, 3, and 4 of the Parent study, CLS1002-101.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartOct 2021
First PostedNov 2021
Primary CompletionJan 2023
TodayJul 2026
First PostedNov 23, 2021
Enrollment StartOct 8, 2021
Primary CompletionJan 5, 2023
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 4.6 years ago
Interventions
CLS-AXdrug
injectable suspension of small molecule tyrosine kinase inhibitor (TKI) administered in the Parent study CLS1002-101